{"mainPropery":{"diseaseId":7578,"diseaseName":"Richter syndrome","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7578/richter-syndrome","synonyms":["Richter transformation"],"synonyms-with-source":[{"name":"Richter transformation","source":"NCI"}],"identifiers":[{"identifierType":"UMLS","identifierId":"C0349631"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":550,"resourceName":"Chronic Lymphocytic Leukemia Information Group","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"","url":"http://www.cllinfogroup.org"},{"resourceID":551,"resourceName":"Lymphoma Research Foundation","abbreviation":"","address1":"Wall Street Plaza","address2":"88 Pine Street, Suite 2400","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10005","country":"United States","phone":"+1-212-349-2910","tty":"","tollFree":"1-800-500-9976","fax":"+1-212-349-2886","email":"helpline@lymphoma.org","url":"https://www.lymphoma.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%28Richter%5BAll%20Fields%5D%20AND%20%28%22syndrome%22%5BMeSH%20Terms%5D%20OR%20%22syndrome%22%5BAll%20Fields%5D%29%29%20AND%20%28%22loattrfree%20full%20text%22%5Bsb%5D%20AND%20hasabstract%5Btext%5D%20AND%20%22humans%22%5BMeSH%20Terms%5D%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Richter syndrome. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Richter+syndrome%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Richter syndrome. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":779,"resourceId":551,"resourceName":"Lymphoma Research Foundation","descriptionText":"The Lymphoma Research Foundation provides information about <a href='http://www.lymphoma.org/site/pp.asp?c=chKOI6PEImE&amp;b=1573973#sll ' target='_blank'>chronic lymphocytic leukemia</a> and <a href='http://www.lymphoma.org/site/pp.asp?c=chKOI6PEImE&amp;b=3753519 ' target='_blank'>transformed leukemias</a>, including Richter syndrome. Click on the links above to access this information.","resourceClassificationName":"Overview","resourceClassificationSectionName":"General Information"},{"id":780,"resourceId":1463,"resourceName":"National Cancer Institute (NCI) - Richter syndrome","descriptionText":"The National Cancer Institute (NCI) provides information related to the management of Richter syndrome. Information about treatment of <a href='http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional ' target='_blank'>adult non-hodgkin lymphoma</a> and <a href='http://www.cancer.gov/cancertopics/pdq/treatment/CLL/healthprofessional ' target='_blank'>chronic lymphocytic leukemia</a> can be accessed at the above links.","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":781,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The American Cancer Society provides information about the treatment of Richter syndrome within a report on <a href='http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Treatment_of_Chronic_Lymphocytic_Leukemia_by_Risk_Group.asp?rnav=cri ' target='_blank'>chronic lymphocytic leukemia</a>. Click on the link above to access this information.","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/reporter.cfm' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/dictionary/?CdrID=489396' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:1703' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":2789,"questionText":"What is Richter syndrome?","answerText":"<strong>Richter syndrome</strong> is&nbsp;a rare condition in which chronic lymphocytic leukemia (CLL) changes into a fast-growing type of lymphoma. Symptoms of Richter syndrome can&nbsp;include fever, loss of weight and muscle mass, abdominal pain, and enlargement of the lymph nodes, liver, and spleen.&nbsp;Laboratory results may show <a href=\"http://ghr.nlm.nih.gov/glossary=anemia\" target=\"_blank\">anemia</a> and low <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003647.htm\" target=\"_blank\">platelet counts</a> (which can lead to easy bleeding and bruising).[1810][7081]","dateModified":"2014-01-03T15:39:00"},"basicQuestions":[{"questionId":7185,"questionText":"Are there any recent advancements in the treatment of Richter syndrome?","answerText":"Monoclonal antibodies (MABs) are a type of <a href=\"http://www.cancer.gov/cancertopics/treatment/biologicaltherapy\" target=\"_blank\">biological therapy</a>. They are man-made proteins that target specific proteins on cancer cells. MABs are a fairly new treatment for cancer. Doctors often use the MAB drug called <a href=\"http://www.cancer.gov/cancertopics/druginfo/rituximab\" target=\"_blank\">rituximab</a>&nbsp;along with&nbsp; chemotherapy and <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">steroids</a> to treat Richter syndrome. Researchers in a trial called the CHOP-OR study are studying whether a new biological therapy similar to rituximab can make CHOP chemotherapy work better. The new&nbsp;biological therapy drug&nbsp;is called <a href=\"http://www.cancer.gov/cancertopics/druginfo/ofatumumab\" target=\"_blank\">ofatumumab (Arzerra)</a>. People who have been recently diagnosed with Richter syndrome can participate in this study. The study has two parts. First, patients have ofatumumab with CHOP chemotherapy to eliminate the lymphoma (this is called induction treatment). They then have more ofatumumab on its own to try to stop the lymphoma from&nbsp;coming back (this is called maintenance treatment). <a href=\"http://clinicaltrials.gov/ct2/show/NCT01171378?term=richter&amp;rank=1\" target=\"_blank\">CLICK HERE</a> to learn more about this study.<br />\r\n<br />\r\n<a href=\"http://www.cancer.gov/dictionary?cdrid=270732\" target=\"_blank\">Stem cell transplant </a>is another way of treating Richter syndrome. While only a few people have undergone stem cell transplant for treatment of this disease, so far it has appeared to work quite well. The disease was controlled for longer than in people having normal dose chemotherapy. However,&nbsp;because&nbsp;stem cell transplants have serious side effects and complications,&nbsp;they are only suitable for a small group of people. More research is needed before we can truly&nbsp;find out&nbsp;how&nbsp;well stem cell treatment works for people with Richter syndrome.[7082]<br />\r\n<br />\r\nA recent study showed that a chemotherapy regimen called OFAR (a combination of oxaliplatin, fludarabine, cytarabine, and rituximab)&nbsp;had significant antileukemic activity in&nbsp;patients with Richter syndrome&nbsp;and relapsed/refractory CLL. Patients&nbsp;who underwent stem cell therapy&nbsp;as post-remission therapy had even more favorable outcomes.[7083]","dateModified":"2014-01-03T15:36:00","resourceClassificationName":"Treatment","references":[{"referenceId":7082,"authors":"Cancer Research UK","articleTitle":"Richter's syndrome","bookWebsiteJournalTitle":"","date":"Last updated: 05/01/2013","volume":"","pages":"","url":"http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/what-is-richters-syndrome","dateAccessed":"2014-01-03T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7083,"authors":"Tsimberidou AM, Wierda WG, Wen S et al","articleTitle":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome","bookWebsiteJournalTitle":"","date":"2013 Oct","volume":"13(5)","pages":"568-74","url":"http://www.ncbi.nlm.nih.gov/pubmed/23810245","dateAccessed":"2014-01-03T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":43000,"abbreviatedInquiry":"My uncle has been diagnosed with Ricter syndrome. His doctor mentioned stem cell transplant as a possible treatment. Can you let me know about any advancements in treatment of this disease which could help him?\r\n\r\n\r\n\r\n","caseQuestions":[{"questionId":7185,"questionText":"Are there any recent advancements in the treatment of Richter syndrome?","answerText":"Monoclonal antibodies (MABs) are a type of <a href=\"http://www.cancer.gov/cancertopics/treatment/biologicaltherapy\" target=\"_blank\">biological therapy</a>. They are man-made proteins that target specific proteins on cancer cells. MABs are a fairly new treatment for cancer. Doctors often use the MAB drug called <a href=\"http://www.cancer.gov/cancertopics/druginfo/rituximab\" target=\"_blank\">rituximab</a>&nbsp;along with&nbsp; chemotherapy and <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">steroids</a> to treat Richter syndrome. Researchers in a trial called the CHOP-OR study are studying whether a new biological therapy similar to rituximab can make CHOP chemotherapy work better. The new&nbsp;biological therapy drug&nbsp;is called <a href=\"http://www.cancer.gov/cancertopics/druginfo/ofatumumab\" target=\"_blank\">ofatumumab (Arzerra)</a>. People who have been recently diagnosed with Richter syndrome can participate in this study. The study has two parts. First, patients have ofatumumab with CHOP chemotherapy to eliminate the lymphoma (this is called induction treatment). They then have more ofatumumab on its own to try to stop the lymphoma from&nbsp;coming back (this is called maintenance treatment). <a href=\"http://clinicaltrials.gov/ct2/show/NCT01171378?term=richter&amp;rank=1\" target=\"_blank\">CLICK HERE</a> to learn more about this study.<br />\r\n<br />\r\n<a href=\"http://www.cancer.gov/dictionary?cdrid=270732\" target=\"_blank\">Stem cell transplant </a>is another way of treating Richter syndrome. While only a few people have undergone stem cell transplant for treatment of this disease, so far it has appeared to work quite well. The disease was controlled for longer than in people having normal dose chemotherapy. However,&nbsp;because&nbsp;stem cell transplants have serious side effects and complications,&nbsp;they are only suitable for a small group of people. More research is needed before we can truly&nbsp;find out&nbsp;how&nbsp;well stem cell treatment works for people with Richter syndrome.[7082]<br />\r\n<br />\r\nA recent study showed that a chemotherapy regimen called OFAR (a combination of oxaliplatin, fludarabine, cytarabine, and rituximab)&nbsp;had significant antileukemic activity in&nbsp;patients with Richter syndrome&nbsp;and relapsed/refractory CLL. Patients&nbsp;who underwent stem cell therapy&nbsp;as post-remission therapy had even more favorable outcomes.[7083]","dateModified":"2014-01-03T15:36:00","resourceClassificationName":"Treatment","references":[{"referenceId":7082,"authors":"Cancer Research UK","articleTitle":"Richter's syndrome","bookWebsiteJournalTitle":"","date":"Last updated: 05/01/2013","volume":"","pages":"","url":"http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/what-is-richters-syndrome","dateAccessed":"2014-01-03T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7083,"authors":"Tsimberidou AM, Wierda WG, Wen S et al","articleTitle":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome","bookWebsiteJournalTitle":"","date":"2013 Oct","volume":"13(5)","pages":"568-74","url":"http://www.ncbi.nlm.nih.gov/pubmed/23810245","dateAccessed":"2014-01-03T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Richter_syndrome"}